<DOC>
	<DOCNO>NCT01908335</DOCNO>
	<brief_summary>This dose-escalating study evaluate efficacy safety different dose new bio-product Pegylated Recombinant Consensus Interferon Variant Solution Injection ( PEG-IFN-SA ) Ribavirin（RBV） treatment Chronic hepatitis C previously treat Interferon ( IFN ) explore dose-effect relationship , identity optimal dose phase Ⅲ study . In addition , population pharmacokinetic method adopt assess pharmacokinetic behavior , individual / intra-individual variability , possible factor study .</brief_summary>
	<brief_title>A Phase Ⅱ Dose-escalating Study PEG-IFN-SA Ribavirin IFN Naive Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Total 200 subject randomize enrol four group proportionally receive experimental drug high dose , middle dose , low dose positive-control drug . Treatment duration 24 48 week correspond different HCV genotype , genotype 2,3 non-genotype2,3 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age 18 65 year Body Mass Index ( BMI ) 1830 Chronic hepatitis C , diagnose accord Chinese guideline Hepatitis C ( year 2004 ) Detectable serum HCVRNA quantitative polymerase chain reaction assay positive antiHCV antibody Female subject childbearing age history menopause negative pregnancy test , female male ( include partner ) subject require conduct adequate contraception since screen 6 month treatment Volunteered participate study , understood sign informed consent Previous IFN treat patient Coinfection HAV , HBV , HEV , EBV , CMV HIV Evidences hepatic decompensation , include limited serum total bilirubin &gt; 2 time upper limit normal ( ULN ) ; serum albumin &lt; 35g/L ; prothrombin activity ( PTA ) &lt; 60 % ; ascites , upper gastrointestinal bleeding hepatic encephalopathy ; ChildPugh score B/C grade Hepatotoxic drug use long time within past 6 month Diagnosed primary hepatocellular carcinoma support evidence include limited AFP &gt; l00ng/ml , suspicious liver nodule image examination Liver diseases cause HCV infection , include alcoholic liver disease , nonalcoholic steatohepatitis , druginduced hepatitis , autoimmune hepatitis ( antinuclear antibody titer high 1:100 ) , hepatolenticular degeneration ( Wilson 's disease ) hemochromatosis , etc . White blood cell count &lt; 3×109/L ; Neutrophil count &lt; 1.5×109/L ; platelet count &lt; 90×109/L ; hemoglobin low limit normal Serum creatinine within normal range Serum creatine kinase &gt; 3 ULN Positive thyroid antibody ( ATPO , ATG ) Therapy potent immunomodulatory agent adrenocorticotropic hormone , thymosin α1 etc . within past 6 month anticipate usage period study Allergies severe allergy , especially allergic study drug ingredient study drug Severe autoimmune disease ; psychiatric nervous system disorder , include history Psychiatric illness family history ( especially depression , depressive tendency , epilepsy hysteria , etc . ) ; Serious blood disorder ( kind anemia , hemophilia , etc . ) ; Severe kidney disease ( chronic kidney disease , renal insufficiency , etc . ) ; poorly control digestive disease ; endocrine disorder thyroid disease diabetes ; severe respiratory disease ( pneumonia , chronic obstructive pulmonary disease , interstitial lung disease , etc . ) ; cardiovascular disease ( hypertension , uncontrolled coronary atherosclerotic heart disease , heart failure , etc . ) ; retinal disease ; malignancy ; unsuitable study consider clinician Function organ transplant Evidence alcohol drug abuse ( average alcohol consumption male &gt; 40g / day , female &gt; 20g / day ) Pregnant lactate woman Usage prohibition drug study Participated clinical trial 3 month prior screen Unwilling sign inform consent adhere treatment requirement Other condition suitable study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>virological response</keyword>
</DOC>